By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Galapagos NV 

Industriepark Mechelen Noord I, Zone L
Generaal De Wittelaan 11 A
Mechelen    B-2800  Belgium
Phone: 32-15-34-29-00 Fax: 32-15-34-29-01



Company News
Galapagos (GLPG.BR) Initiates Phase 1 First-In-Human Study With GLPG1972, Receives €3.5 Million Milestone From Servier 11/20/2015 9:00:53 AM
Galapagos (GLPG.BR) Reports Third Quarter 2015 Cash Position Of €374 Million 11/13/2015 10:07:15 AM
Galapagos (GLPG.BR) Builds On Strong Profile Of Filgotinib In 7 Presentations At American College of Rheumatology 2015 11/9/2015 10:54:56 AM
Dr. Christine Mummery Appointed To Galapagos (GLPG.BR)' Board Of Directors 11/4/2015 1:42:33 PM
Galapagos (GLPG.BR) Raises €1.2 Million Through Warrant Exercises 10/5/2015 9:10:45 AM
Galapagos (GLPG.BR) To Advance Filgotinib To Phase 3 In Rheumatoid Arthritis 9/25/2015 9:59:32 AM
AbbVie (ABBV) Walks Away from $1.4 Billion Arthritis Deal with Galapagos (GLPG.BR) to Develop Its Own Drug Instead 9/25/2015 7:01:55 AM
Galapagos (GLPG.BR) Presents Promising Pre-Clinical And Phase 1 Results With Autotaxin Inhibitor GLPG1690 At ERS 9/22/2015 9:18:16 AM
Galapagos (GLPG.BR) Release: Patient Recruitment Completed In FITZROY Phase 2 Crohn's Disease Study With Filgotinib 8/6/2015 8:33:00 AM
Galapagos (GLPG.BR) On Track To Deliver On Pipeline In Second Half 2015 8/6/2015 8:22:02 AM